Valuation: PTC Therapeutics, Inc.

Market Cap 5.68B 4.93B 4.59B 4.22B 7.96B 542B 8.09B 54.14B 21.25B 270B 21.32B 20.85B 905B P/E 2026 *
41.2x
P/E 2027 * 24.6x
Enterprise Value 3.81B 3.31B 3.08B 2.83B 5.34B 363B 5.42B 36.29B 14.24B 181B 14.29B 13.98B 606B EV / Sales 2026 *
3.07x
EV / Sales 2027 * 2.61x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
1 day-9.94%
1 week-11.47%
1 month-16.62%
3 months+4.53%
6 months-9.96%
Current year-10.47%
1 week 64.57
Extreme 64.5675
79.33
1 month 64.57
Extreme 64.5675
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
14/7/26 Sell

Chief Financial Officer

-3,494 0.0042%
9/7/26 Fiscal year

Chief Technology Officer

7,392 0.0089%
9/7/26 Fiscal year

Director

47,502 0.0573%
Change 5-day change 1-year change 3-year change Capi.($)
-9.94%-11.47%+30.51%+68.59% 5.68B
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -2.24%-2.22%+30.15%+51.64% 357.94B
Weighted average by Cap. -1.00%-1.95%+39.22%+72.95%

Financials

2026 *2027 *
Net sales 1.24B 1.08B 1B 922M 1.74B 118B 1.77B 11.83B 4.64B 58.95B 4.66B 4.56B 198B 1.35B 1.17B 1.09B 1B 1.9B 129B 1.93B 12.89B 5.06B 64.22B 5.07B 4.96B 215B
Net income 132M 115M 107M 98.32M 186M 12.63B 189M 1.26B 495M 6.29B 497M 486M 21.09B 194M 169M 157M 144M 273M 18.56B 277M 1.85B 728M 9.24B 730M 714M 30.99B
Net Debt -1.87B -1.63B -1.51B -1.39B -2.62B -179B -2.67B -17.85B -7B -88.92B -7.03B -6.87B -298B -2.15B -1.86B -1.74B -1.59B -3.01B -205B -3.06B -20.46B -8.03B -102B -8.06B -7.88B -342B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
31/07/26 USD 68.01 -9.94% 4,329,705
30/07/26 USD 75.52 +1.38% 1,374,880
29/07/26 USD 74.49 -1.19% 1,173,858
28/07/26 USD 75.39 -0.54% 1,487,692
27/07/26 USD 75.80 -1.33% 1,852,688
Trader
Investor
Global
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
68.02USD
Average target price
96.93USD
Spread / Average Target
+42.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock